In this online, self-learning activity:
Osteoporosis is a disease common among elderly patients that is increasing in frequency as senior citizens begin to represent a larger share of the U.S. population. Osteoporosis increases the risk of severe fracture, which, in turn, is associated with a higher risk of mortality. A variety of literature has demonstrated that antiresorptive therapy is effective at reducing the progression of disease and preventing fracture; however, recent studies have demonstrated that these therapies have a variety of adverse effects,some of which – like osteonecrosis of the jaw and atypical fractures – are severe and were unrecognized at the time of their initial FDA approval. These emerging concerns are raising questions as to the optimal duration of treatment and potential benefit of a drug holiday.
The following healthcare professionals: endocrinologists, geriatricians, internists; physician assistants, nurse practitioners, nurses, and pharmacists who specialize in those areas of medicine; those who otherwise commonly care for patients with osteoporosis.
Commercial Support Disclosure: This program is supported by an educational grant from Radius Health.
Release Date: September 30, 2018 -- Expiration Date: September 30, 2020
Faculty: Yousaf Ali, MD, FACR
Faculty introduction, disclosures
Introduction content: cursory refresher and review of osteoporosis
Treatment and prevention of osteoporosis
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
THIS COURSE IS EXPIRED. NO CREDIT WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Ali, MD, Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.
Commercial Support Disclosure: This activity is supported by an educational grant from Radius Health.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Optimizing Primary and Secondary Fracture Prevention in Men with Osteoporosis
Male Osteoporosis Management: Advances in Pharmacotherapy